603965-77-1

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate is used as a building block for the synthesis of various drugs and bioactive compounds, contributing to the development of new medications and therapies.
Used in Antiviral and Antimicrobial Applications:
Due to its potential biological activities, Ethyl 2-(piperazin-1-yl)pyrimidine-5-carboxylate is used as a compound with antiviral or antimicrobial properties, which can be further explored and developed for treating infections and diseases.

InChI:InChI=1/C11H16N4O2/c1-2-17-10(16)9-7-13-11(14-8-9)15-5-3-12-4-6-15/h7-8,12H,2-6H2,1H3

Upstream product

• 64-17-5 ethanol 
• 253315-11-6 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid 
• 89793-12-4 ethyl 2-chloropyrimidine-5-carboxylate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 374930-88-8 tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate 
• 2974-30-3 (Z)-ethyl-2-(ethoxymethyl)-3-methoxyacrylate 
• 148550-51-0 ethyl 2-(methylsulfonyl)pyrimidine-5-carboxylate 
• 253315-69-4 ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylate 
• 879008-23-8 (Z)-ethyl-2-(ethoxymethyl)-3-methoxyacrylate 
• 95928-49-7 ethyl 2-oxo-1,2-dihydropyrimidine-5-carboxylate 
• 763-69-9 ethyl 3-ethoxypropionate 
• 33458-27-4 ethyl 2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 110-85-0 piperazine 

Downstream Products

• 944541-49-5 C₂₁H₂₆N₄O₃ 
• 1208144-56-2 C₂₁H₂₆N₄O₂ 
• 1417790-19-2 ethyl 2-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)-pyrimidine-5-carboxylate 
• 842170-25-6 C₂₂H₂₆F₃N₅O₂ 
• 603991-95-3 C₂₃H₂₃N₅O₃ 
• 935670-64-7 C₂₇H₂₅N₅O₄ 
• 875138-60-6 C₂₁H₂₆N₄O₂ 
• 875138-55-9 C₂₁H₂₅ClN₄O₃ 

Relevant academic research and scientific papers

Compound for inducing BCR-ABL protein degradation through targeted ubiquitination and application thereof

The invention provides a compound for inducing BCR-ABL protein degradation through targeted ubiquitination. The compound has the advantages that the compound not only has excellent BCR-ABL protein degradation effect and anti-tumor activity, but also has small toxic and side effects on human bodies, and can be used for preparing anti-tumor drugs.

Androgen receptor inhibitor and application thereof

The invention relates to the field of pharmacy, and particularly discloses an androgen receptor (AR) regulator combined with E3 ubiquitin ligase ligand or a salt thereof. Isomer and contains their pharmaceutical compositions.

METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS

The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.

C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS

The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.

MDM2-HDAC double-target inhibitor, medicinal composition and preparation and application of MDM2-HDAC double-target inhibitor

The invention provides a MDM2-HDAC double-target inhibitor, a medicinal composition and preparation and application of the MDM2-HDAC double-target inhibitor. The MDM2-HDAC double-target inhibitor hasa structure as shown in formula I. The inhibitor with th

ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES

The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and in particular as glycosidase inhibitors.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT

Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a -(C=O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases.

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease

Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit), and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing (Cuadrado-Tejedor, M.; Garcia-Barroso, C.; Sánchez-Arias, J. A.; Rabal, O.; Mederos, S.; Ugarte, A.; Franco, R.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A. Neuropsychopharmacology 2016, in press, doi: 10.1038/npp.2016.163).

Inhibitors of histone deacetylase

This invention comprises the novel compounds of formula (I) wherein n, R1, R2, R3, R4, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositi